Advertisement

Inflammatory Microenvironment Modulation of Alternative Splicing in Cancer: A Way to Adapt

  • Ana Luísa Silva
  • Márcia Faria
  • Paulo Matos
Chapter
  • 215 Downloads
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1219)

Abstract

The relationship between inflammation and cancer has been long recognized by the medical and scientific community. In the last decades, it has returned to the forefront of clinical oncology since a wealth of knowledge has been gathered about the cells, cytokines and physiological processes that are central to both inflammation and cancer. It is now robustly established that chronic inflammation can induce certain cancers but also that solid tumors, in turn, can initiate and perpetuate local inflammatory processes that foster tumor growth and dissemination. Inflammation is the hallmark of the innate immune response to tissue damage or infection, but also mediates the activation, expansion and recruitment to the tissues of cells and antibodies of the adaptive immune system. The functional integration of both components of the immune response is crucial to identify and subdue tumor development, progression and dissemination. When this tight control goes awry, altered cells can avoid the immune surveillance and even subvert the innate immunity to promote their full oncogenic transformation. In this chapter, we make a general overview of the most recent data linking the inflammatory process to cancer. We start with the overall inflammatory cues and processes that influence the relationship between tumor and the microenvironment that surrounds it and follow the ever-increasing complexity of processes that end up producing subtle changes in the splicing of certain genes to ascertain survival advantage to cancer cells.

Keywords

Cancer Inflammation Tumor microenvironment Splicing Signaling 

References

  1. Adegboyega PA, Ololade O, Saada J, Mifflin R, Di Mari JF, Powell DW (2004) Subepithelial myofibroblasts express cyclooxygenase-2 in colorectal tubular adenomas. Clin Cancer Res Off J Am Assoc Cancer Res 10:5870–5879.  https://doi.org/10.1158/1078-0432.CCR-0431-03CrossRefGoogle Scholar
  2. Agrawal AA, Yu L, Smith PG, Buonamici S (2018) Targeting splicing abnormalities in cancer. Curr Opin Genet Dev 48:67–74.  https://doi.org/10.1016/j.gde.2017.10.010CrossRefPubMedGoogle Scholar
  3. Anil C, Goksel S, Gursoy A (2010) Hashimoto’s thyroiditis is not associated with increased risk of thyroid cancer in patients with thyroid nodules: a single-center prospective study. Thyroid Off J Am Thyroid Assoc 20:601–606.  https://doi.org/10.1089/thy.2009.0450CrossRefGoogle Scholar
  4. Bellahcène A, Castronovo V, Ogbureke KUE, Fisher LW, Fedarko NS (2008) Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer 8:212–226.  https://doi.org/10.1038/nrc2345CrossRefPubMedPubMedCentralGoogle Scholar
  5. Boi F, Pani F, Mariotti S (2017) Thyroid autoimmunity and thyroid cancer: review focused on cytological studies. Eur Thyroid J 6:178–186.  https://doi.org/10.1159/000468928CrossRefPubMedPubMedCentralGoogle Scholar
  6. Briones-Orta MA, Avendaño-Vázquez SE, Aparicio-Bautista DI, Coombes JD, Weber GF, Syn W-K (2017) Osteopontin splice variants and polymorphisms in cancer progression and prognosis. Biochim Biophys Acta BBA – Rev Cancer 1868:93–108.  https://doi.org/10.1016/j.bbcan.2017.02.005CrossRefGoogle Scholar
  7. Brosseau J-P, Lucier J-F, Nwilati H, Thibault P, Garneau D, Gendron D, Durand M, Couture S, Lapointe E, Prinos P, Klinck R, Perreault J-P, Chabot B, Abou-Elela S (2014) Tumor microenvironment-associated modifications of alternative splicing. RNA 20:189–201.  https://doi.org/10.1261/rna.042168.113CrossRefPubMedPubMedCentralGoogle Scholar
  8. Castagna MG, Belardini V, Memmo S, Maino F, Di Santo A, Toti P, Carli AF, Caruso G, Pacini F (2014) Nodules in autoimmune thyroiditis are associated with increased risk of thyroid cancer in surgical series but not in cytological series: evidence for selection bias. J Clin Endocrinol Metab 99:3193–3198.  https://doi.org/10.1210/jc.2014-1302CrossRefPubMedGoogle Scholar
  9. Castello LM, Raineri D, Salmi L, Clemente N, Vaschetto R, Quaglia M, Garzaro M, Gentilli S, Navalesi P, Cantaluppi V, Dianzani U, Aspesi A, Chiocchetti A (2017) Osteopontin at the crossroads of inflammation and tumor progression. Mediat Inflamm 2017:1–22.  https://doi.org/10.1155/2017/4049098CrossRefGoogle Scholar
  10. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS (2005) Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310:1504–1510.  https://doi.org/10.1126/science.1116221CrossRefPubMedGoogle Scholar
  11. Chen M, Zhang J, Manley JL (2010) Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA. Cancer Res 70:8977–8980.  https://doi.org/10.1158/0008-5472.CAN-10-2513CrossRefPubMedPubMedCentralGoogle Scholar
  12. Cheng C, Yaffe MB, Sharp PA (2006) A positive feedback loop couples Ras activation and CD44 alternative splicing. Genes Dev 20:1715–1720.  https://doi.org/10.1101/gad.1430906CrossRefPubMedPubMedCentralGoogle Scholar
  13. Climente-González H, Porta-Pardo E, Godzik A, Eyras E (2017) The functional impact of alternative splicing in cancer. Cell Rep 20:2215–2226.  https://doi.org/10.1016/j.celrep.2017.08.012CrossRefPubMedGoogle Scholar
  14. Clower CV, Chatterjee D, Wang Z, Cantley LC, Vander Heiden MG, Krainer AR (2010) The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc Natl Acad Sci U S A 107:1894–1899.  https://doi.org/10.1073/pnas.0914845107CrossRefPubMedPubMedCentralGoogle Scholar
  15. Correa P (1995) Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol 19(Suppl 1):S37–S43PubMedGoogle Scholar
  16. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867.  https://doi.org/10.1038/nature01322CrossRefPubMedPubMedCentralGoogle Scholar
  17. Dailey ME, Lindsay S, Skahen R (1955) Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg 70:291–297CrossRefGoogle Scholar
  18. David CJ, Chen M, Assanah M, Canoll P, Manley JL (2010) HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463:364–368.  https://doi.org/10.1038/nature08697CrossRefPubMedGoogle Scholar
  19. Dery KJ, Kujawski M, Grunert D, Wu X, Ngyuen T, Cheung C, Yim JH, Shively JE (2014) IRF-1 regulates alternative mRNA splicing of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in breast epithelial cells generating an immunoreceptor tyrosine-based inhibition motif (ITIM) containing isoform. Mol Cancer 13:64.  https://doi.org/10.1186/1476-4598-13-64CrossRefPubMedPubMedCentralGoogle Scholar
  20. Devaud C, Tilkin-Mariamé A-F, Vignolle-Vidoni A, Souleres P, Denadai-Souza A, Rolland C, Duthoit C, Blanpied C, Chabot S, Bouillé P, Lluel P, Vergnolle N, Racaud-Sultan C, Ferrand A (2019) FAK alternative splice mRNA variants expression pattern in colorectal cancer: FAK alternative splice mRNA variants expression pattern in colorectal cancer. Int J Cancer.  https://doi.org/10.1002/ijc.32120CrossRefGoogle Scholar
  21. Dong YH, Fu DG (2014) Autoimmune thyroid disease: mechanism, genetics and current knowledge. Eur Rev Med Pharmacol Sci 18:3611–3618PubMedGoogle Scholar
  22. Dvinge H (2018) Regulation of alternative mRNA splicing: old players and new perspectives. FEBS Lett 592:2987–3006.  https://doi.org/10.1002/1873-3468.13119CrossRefPubMedGoogle Scholar
  23. Faria M, Capinha L, Simões-Pereira J, Bugalho MJ, Silva AL (2016) Extending the impact of RAC1b overexpression to follicular thyroid carcinomas. Int J Endocrinol 2016:1972367.  https://doi.org/10.1155/2016/1972367CrossRefPubMedPubMedCentralGoogle Scholar
  24. Faria M, Matos P, Pereira T, Cabrera R, Cardoso BA, Bugalho MJ, Silva AL (2017) RAC1b overexpression stimulates proliferation and NF-kB-mediated anti-apoptotic signaling in thyroid cancer cells. PLoS One 12:e0172689.  https://doi.org/10.1371/journal.pone.0172689CrossRefPubMedPubMedCentralGoogle Scholar
  25. Ferreira LB, Tavares C, Pestana A, Pereira CL, Eloy C, Pinto MT, Castro P, Batista R, Rios E, Sobrinho-Simões M, Gimba ERP, Soares P (2016) Osteopontin-a splice variant is overexpressed in papillary thyroid carcinoma and modulates invasive behavior. Oncotarget 7.  https://doi.org/10.18632/oncotarget.10468
  26. Fiegen D, Haeusler L-C, Blumenstein L, Herbrand U, Dvorsky R, Vetter IR, Ahmadian MR (2004) Alternative splicing of Rac1 generates Rac1b, a self-activating GTPase. J Biol Chem 279:4743–4749.  https://doi.org/10.1074/jbc.M310281200CrossRefPubMedGoogle Scholar
  27. Fodde R, Smits R, Clevers H (2001) APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 1:55–67.  https://doi.org/10.1038/35094067CrossRefPubMedGoogle Scholar
  28. Fouad YA, Aanei C (2017) Revisiting the hallmarks of cancer. Am J Cancer Res 7:1016–1036PubMedPubMedCentralGoogle Scholar
  29. Fugazzola L, Colombo C, Perrino M, Muzza M (2011) Papillary thyroid carcinoma and inflammation. Front Endocrinol 2.  https://doi.org/10.3389/fendo.2011.00088
  30. Galizia G, Orditura M, Romano C, Lieto E, Castellano P, Pelosio L, Imperatore V, Catalano G, Pignatelli C, De Vita F (2002) Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol Orlando Fla 102:169–178.  https://doi.org/10.1006/clim.2001.5163CrossRefGoogle Scholar
  31. Georgilis A, Klotz S, Hanley CJ, Herranz N, Weirich B, Morancho B, Leote AC, D’Artista L, Gallage S, Seehawer M, Carroll T, Dharmalingam G, Wee KB, Mellone M, Pombo J, Heide D, Guccione E, Arribas J, Barbosa-Morais NL, Heikenwalder M, Thomas GJ, Zender L, Gil J (2018) PTBP1-mediated alternative splicing regulates the inflammatory Secretome and the pro-tumorigenic effects of senescent cells. Cancer Cell 34:85–102.e9.  https://doi.org/10.1016/j.ccell.2018.06.007CrossRefPubMedPubMedCentralGoogle Scholar
  32. Gimba ER, Tilli TM (2013) Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways. Cancer Lett 331:11–17.  https://doi.org/10.1016/j.canlet.2012.12.003CrossRefPubMedGoogle Scholar
  33. Giorgio M, Maria Z, Maria C, Marco I, Martina S, Gianna F, Eliana C, Giovanna R (2013) Pro-inflammatory cytokines analysis in HPV-positive cancer cells. Front Immunol 4.  https://doi.org/10.3389/conf.fimmu.2013.02.00306
  34. Gomaa W, Al-Ahwal M, Hamour O, Al-Maghrabi J (2013) Osteopontin cytoplasmic immunoexpression is a predictor of poor disease-free survival in thyroid cancer. J Microsc Ultrastruct 1:8.  https://doi.org/10.1016/j.jmau.2013.07.001CrossRefGoogle Scholar
  35. Gonçalves V, Matos P, Jordan P (2009) Antagonistic SR proteins regulate alternative splicing of tumor-related Rac1b downstream of the PI3-kinase and Wnt pathways. Hum Mol Genet 18:3696–3707.  https://doi.org/10.1093/hmg/ddp317CrossRefPubMedGoogle Scholar
  36. Gonçalves V, Henriques AFA, Henriques A, Pereira JFS, Pereira J, Neves Costa A, Moyer MP, Moita LF, Gama-Carvalho M, Matos P, Jordan P (2014) Phosphorylation of SRSF1 by SRPK1 regulates alternative splicing of tumor-related Rac1b in colorectal cells. RNA 20:474–482.  https://doi.org/10.1261/rna.041376.113CrossRefPubMedPubMedCentralGoogle Scholar
  37. Gonçalves V, Pereira J, Jordan P (2017) Signaling pathways driving aberrant splicing in cancer cells. Genes 9:9.  https://doi.org/10.3390/genes9010009CrossRefPubMedCentralGoogle Scholar
  38. Gonzalez-Zubeldia I, Dotor J, Redrado M, Bleau A-M, Manrique I, de Aberasturi AL, Villalba M, Calvo A (2015) Co-migration of colon cancer cells and CAFs induced by TGFβ1 enhances liver metastasis. Cell Tissue Res 359:829–839.  https://doi.org/10.1007/s00441-014-2075-6CrossRefPubMedGoogle Scholar
  39. Grivennikov SI (2013) Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol 35:229–244.  https://doi.org/10.1007/s00281-012-0352-6CrossRefPubMedGoogle Scholar
  40. Grivennikov S, Karin E, Terzic J, Mucida D, Yu G-Y, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, Karin M (2009) IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15:103–113.  https://doi.org/10.1016/j.ccr.2009.01.001CrossRefPubMedPubMedCentralGoogle Scholar
  41. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883–899.  https://doi.org/10.1016/j.cell.2010.01.025CrossRefPubMedPubMedCentralGoogle Scholar
  42. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674.  https://doi.org/10.1016/j.cell.2011.02.013CrossRefGoogle Scholar
  43. Hassuneh MR, Nagarkatti M, Nagarkatti PS (2013) Role of interleukin-10 in the regulation of tumorigenicity of a T cell lymphoma. Leuk Lymphoma 54:827–834.  https://doi.org/10.3109/10428194.2012.726721CrossRefPubMedPubMedCentralGoogle Scholar
  44. Hayes GM, Carrigan PE, Miller LJ (2007) Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res 67:2072–2080.  https://doi.org/10.1158/0008-5472.CAN-06-2969CrossRefPubMedGoogle Scholar
  45. Herbeuval J-P, Lelievre E, Lambert C, Dy M, Genin C (2004) Recruitment of STAT3 for production of IL-10 by colon carcinoma cells induced by macrophage-derived IL-6. J Immunol Baltim Md 172:4630–4636Google Scholar
  46. Hermiston ML, Xu Z, Weiss A (2003) CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol 21:107–137.  https://doi.org/10.1146/annurev.immunol.21.120601.140946CrossRefPubMedGoogle Scholar
  47. Hollander D, Donyo M, Atias N, Mekahel K, Melamed Z, Yannai S, Lev-Maor G, Shilo A, Schwartz S, Barshack I, Sharan R, Ast G (2016) A network-based analysis of colon cancer splicing changes reveals a tumorigenesis-favoring regulatory pathway emanating from ELK1. Genome Res 26:541–553.  https://doi.org/10.1101/gr.193169.115CrossRefPubMedPubMedCentralGoogle Scholar
  48. Jankovic B, Le KT, Hershman JM (2013) Hashimoto’s thyroiditis and papillary thyroid carcinoma: is there a correlation? J Clin Endocrinol Metab 98:474–482.  https://doi.org/10.1210/jc.2012-2978CrossRefPubMedGoogle Scholar
  49. Jedinak A, Dudhgaonkar S, Sliva D (2010) Activated macrophages induce metastatic behavior of colon cancer cells. Immunobiology 215:242–249.  https://doi.org/10.1016/j.imbio.2009.03.004CrossRefPubMedGoogle Scholar
  50. Jordan P, Brazåo R, Boavida MG, Gespach C, Chastre E (1999) Cloning of a novel human Rac1b splice variant with increased expression in colorectal tumors. Oncogene 18:6835–6839.  https://doi.org/10.1038/sj.onc.1203233CrossRefPubMedGoogle Scholar
  51. Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9:239–252.  https://doi.org/10.1038/nrc2618CrossRefGoogle Scholar
  52. Kaler P, Godasi BN, Augenlicht L, Klampfer L (2009) The NF-κB/AKT-dependent induction of Wnt signaling in colon cancer cells by macrophages and IL-1β. Cancer Microenviron Off J Int Cancer Microenviron Soc 2:69–80.  https://doi.org/10.1007/s12307-009-0030-yCrossRefGoogle Scholar
  53. Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M (2019) Molecular mechanisms driving progression of liver cirrhosis towards hepatocellular carcinoma in chronic hepatitis B and C infections: a review. Int J Mol Sci 20.  https://doi.org/10.3390/ijms20061358CrossRefGoogle Scholar
  54. Kazanecki CC, Uzwiak DJ, Denhardt DT (2007) Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem 102:912–924.  https://doi.org/10.1002/jcb.21558CrossRefPubMedGoogle Scholar
  55. Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141:52–67.  https://doi.org/10.1016/j.cell.2010.03.015CrossRefPubMedPubMedCentralGoogle Scholar
  56. Kim S, Myong JP, Jee H-G, Chai YJ, Choi JY, Min HS, Lee KE, Youn Y-K (2016) Combined effect of Hashimoto’s thyroiditis and BRAF(V600E) mutation status on aggressiveness in papillary thyroid cancer. Head Neck 38:95–101.  https://doi.org/10.1002/hed.23854CrossRefPubMedGoogle Scholar
  57. Kim WW, Ha TK, Bae SK (2018) Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis. J Otolaryngol – Head Neck Surg 47.  https://doi.org/10.1186/s40463-017-0247-6
  58. Klinck R, Bramard A, Inkel L, Dufresne-Martin G, Gervais-Bird J, Madden R, Paquet ER, Koh C, Venables JP, Prinos P, Jilaveanu-Pelmus M, Wellinger R, Rancourt C, Chabot B, Abou Elela S (2008) Multiple alternative splicing markers for ovarian cancer. Cancer Res 68:657–663.  https://doi.org/10.1158/0008-5472.CAN-07-2580CrossRefPubMedGoogle Scholar
  59. Kumari S, Badana AK, MM G, S G, Malla R (2018) Reactive oxygen species: a key constituent in cancer survival. Biomark Insights 13:1177271918755391.  https://doi.org/10.1177/1177271918755391CrossRefPubMedPubMedCentralGoogle Scholar
  60. Lai X, Xia Y, Zhang B, Li J, Jiang Y (2017) A meta-analysis of Hashimoto’s thyroiditis and papillary thyroid carcinoma risk. Oncotarget 8:62414–62424.  https://doi.org/10.18632/oncotarget.18620CrossRefPubMedPubMedCentralGoogle Scholar
  61. Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA (2014) Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014:149185.  https://doi.org/10.1155/2014/149185CrossRefPubMedPubMedCentralGoogle Scholar
  62. Lee SC-W, Abdel-Wahab O (2016) Therapeutic targeting of splicing in cancer. Nat Med 22:976–986.  https://doi.org/10.1038/nm.4165CrossRefPubMedPubMedCentralGoogle Scholar
  63. Lee G, Goretsky T, Managlia E, Dirisina R, Singh AP, Brown JB, May R, Yang G-Y, Ragheb JW, Evers BM, Weber CR, Turner JR, He XC, Katzman RB, Li L, Barrett TA (2010) Phosphoinositide 3-kinase signaling mediates beta-catenin activation in intestinal epithelial stem and progenitor cells in colitis. Gastroenterology 139(869–881):881–889.  https://doi.org/10.1053/j.gastro.2010.05.037CrossRefGoogle Scholar
  64. Li CY, Chu JY, Yu JK, Huang XQ, Liu XJ, Shi L, Che YC, Xie JY (2004) Regulation of alternative splicing of Bcl-x by IL-6, GM-CSF and TPA. Cell Res 14:473–479.  https://doi.org/10.1038/sj.cr.7290250CrossRefPubMedGoogle Scholar
  65. Li H, Fan X, Houghton J (2007) Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem 101:805–815.  https://doi.org/10.1002/jcb.21159CrossRefPubMedGoogle Scholar
  66. Liang J, Zeng W, Fang F, Yu T, Zhao Y, Fan X, Guo N, Gao X (2017) Clinical analysis of Hashimoto thyroiditis coexistent with papillary thyroid cancer in 1392 patients. Acta Otorhinolaryngol Ital Organo Uff Della Soc Ital Otorinolaringol E Chir Cerv-facc 37:393–400.  https://doi.org/10.14639/0392-100X-1709CrossRefGoogle Scholar
  67. Likui W, Hong W, Shuwen Z (2010) Clinical significance of the upregulated Osteopontin mRNA expression in human colorectal Cancer. J Gastrointest Surg 14:74–81.  https://doi.org/10.1007/s11605-009-1035-zCrossRefPubMedGoogle Scholar
  68. Liu S, Cheng C (2013) Alternative RNA splicing and cancer: alternative RNA splicing and cancer. Wiley Interdiscip Rev RNA 4:547–566.  https://doi.org/10.1002/wrna.1178CrossRefPubMedPubMedCentralGoogle Scholar
  69. Liu J, Li H, Shen S, Sun L, Yuan Y, Xing C (2018) Alternative splicing events implicated in carcinogenesis and prognosis of colorectal cancer. J Cancer 9:1754–1764.  https://doi.org/10.7150/jca.24569CrossRefPubMedPubMedCentralGoogle Scholar
  70. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444.  https://doi.org/10.1038/nature07205CrossRefPubMedGoogle Scholar
  71. Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ (2017) Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. Int J Mol Sci 18.  https://doi.org/10.3390/ijms18010197CrossRefGoogle Scholar
  72. Matos P, Jordan P (2005) Expression of Rac1b stimulates NF-kappaB-mediated cell survival and G1/S progression. Exp Cell Res 305:292–299.  https://doi.org/10.1016/j.yexcr.2004.12.029CrossRefPubMedGoogle Scholar
  73. Matos P, Jordan P (2006) Rac1, but not Rac1B, stimulates RelB-mediated gene transcription in colorectal cancer cells. J Biol Chem 281:13724–13732.  https://doi.org/10.1074/jbc.M513243200CrossRefPubMedGoogle Scholar
  74. Matos P, Jordan P (2008) Increased Rac1b expression sustains colorectal tumor cell survival. Mol Cancer Res MCR 6:1178–1184.  https://doi.org/10.1158/1541-7786.MCR-08-0008CrossRefPubMedGoogle Scholar
  75. Matos P, Jordan P (2015) Beyond COX-inhibition: “side-effects” of ibuprofen on neoplastic development and progression. Curr Pharm Des 21:2978–2982CrossRefGoogle Scholar
  76. Matos P, Collard JG, Jordan P (2003) Tumor-related alternatively spliced Rac1b is not regulated by Rho-GDP dissociation inhibitors and exhibits selective downstream signaling. J Biol Chem 278:50442–50448.  https://doi.org/10.1074/jbc.M308215200CrossRefPubMedGoogle Scholar
  77. Matos P, Oliveira C, Velho S, Gonçalves V, da Costa LT, Moyer MP, Seruca R, Jordan P (2008) B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival. Gastroenterology 135:899–906.  https://doi.org/10.1053/j.gastro.2008.05.052CrossRefPubMedGoogle Scholar
  78. Matos P, Kotelevets L, Jordan P, Gonçalves V, Henriques A, Zerbib P, Moyer MP, Chastre E (2013) Ibuprofen inhibits colitis-induced overexpression of tumor related Rac1b. Neoplasia 15:102–111.  https://doi.org/10.1593/neo.121890CrossRefPubMedPubMedCentralGoogle Scholar
  79. Matos P, Gonçalves V, Jordan P (2016) Targeting the serrated pathway of colorectal cancer with mutation in BRAF. Biochim Biophys Acta 1866:51–63.  https://doi.org/10.1016/j.bbcan.2016.06.003CrossRefPubMedGoogle Scholar
  80. Mehner C, Miller E, Nassar A, Bamlet WR, Radisky ES, Radisky DC (2015) Tumor cell expression of MMP3 as a prognostic factor for poor survival in pancreatic, pulmonary, and mammary carcinoma. Genes Cancer 6:480–489.  https://doi.org/10.18632/genesandcancer.90CrossRefPubMedPubMedCentralGoogle Scholar
  81. Melzer C, Hass R, Lehnert H, Ungefroren H (2019) RAC1B: a Rho GTPase with versatile functions in malignant transformation and tumor progression. Cell 8.  https://doi.org/10.3390/cells8010021CrossRefGoogle Scholar
  82. Muñoz Ú, Puche JE, Hannivoort R, Lang UE, Cohen-Naftaly M, Friedman SL (2012) Hepatocyte growth factor enhances alternative splicing of the Kruppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1. Mol Cancer Res MCR 10:1216–1227.  https://doi.org/10.1158/1541-7786.MCR-12-0213CrossRefPubMedGoogle Scholar
  83. Muzza M, Degl’Innocenti D, Colombo C, Perrino M, Ravasi E, Rossi S, Cirello V, Beck-Peccoz P, Borrello MG, Fugazzola L (2010) The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. Clin Endocrinol 72:702–708.  https://doi.org/10.1111/j.1365-2265.2009.03699.xCrossRefGoogle Scholar
  84. Nagayama Y (2018) Thyroid autoimmunity and thyroid cancer – the pathogenic connection: a 2018 update. Horm Metab Res Horm Stoffwechselforschung Horm Metab 50:922–931.  https://doi.org/10.1055/a-0648-4593CrossRefGoogle Scholar
  85. Nakamura K, Smyth MJ (2017) Targeting cancer-related inflammation in the era of immunotherapy. Immunol Cell Biol 95:325–332.  https://doi.org/10.1038/icb.2016.126CrossRefPubMedGoogle Scholar
  86. Oberdoerffer S, Moita LF, Neems D, Freitas RP, Hacohen N, Rao A (2008) Regulation of CD45 alternative splicing by heterogeneous ribonucleoprotein, hnRNPLL. Science 321:686–691.  https://doi.org/10.1126/science.1157610CrossRefPubMedPubMedCentralGoogle Scholar
  87. Oh C-M, Park S, Lee JY, Won Y-J, Shin A, Kong H-J, Choi K-S, Lee YJ, Chung K-W, Jung K-W (2014) Increased prevalence of chronic lymphocytic thyroiditis in Korean patients with papillary thyroid cancer. PLoS One 9:e99054.  https://doi.org/10.1371/journal.pone.0099054CrossRefPubMedPubMedCentralGoogle Scholar
  88. Parascandolo A, Rappa F, Cappello F, Kim J, Cantu DA, Chen H, Mazzoccoli G, Hematti P, Castellone MD, Salvatore M, Laukkanen MO (2017) Extracellular superoxide dismutase expression in papillary thyroid cancer mesenchymal stem/stromal cells modulates cancer cell growth and migration. Sci Rep 7:41416.  https://doi.org/10.1038/srep41416CrossRefPubMedPubMedCentralGoogle Scholar
  89. Pelisch F, Khauv D, Risso G, Stallings-Mann M, Blaustein M, Quadrana L, Radisky DC, Srebrow A (2012) Involvement of hnRNP A1 in the matrix metalloprotease-3-dependent regulation of Rac1 pre-mRNA splicing. J Cell Biochem 113:2319–2329.  https://doi.org/10.1002/jcb.24103CrossRefPubMedPubMedCentralGoogle Scholar
  90. Picon A, Gold LI, Wang J, Cohen A, Friedman E (1998) A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor beta1. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 7:497–504Google Scholar
  91. Pozzi A, Yan X, Macias-Perez I, Wei S, Hata AN, Breyer RM, Morrow JD, Capdevila JH (2004) Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. J Biol Chem 279:29797–29804.  https://doi.org/10.1074/jbc.M313989200CrossRefPubMedGoogle Scholar
  92. Prochazka L, Tesarik R, Turanek J (2014) Regulation of alternative splicing of CD44 in cancer. Cell Signal 26:2234–2239.  https://doi.org/10.1016/j.cellsig.2014.07.011CrossRefPubMedGoogle Scholar
  93. Radisky ES, Radisky DC (2015) Matrix metalloproteinases as breast cancer drivers and therapeutic targets. Front Biosci Landmark Ed 20:1144–1163CrossRefGoogle Scholar
  94. Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, Leake D, Godden EL, Albertson DG, Nieto MA, Werb Z, Bissell MJ (2005) Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436:123–127.  https://doi.org/10.1038/nature03688CrossRefPubMedPubMedCentralGoogle Scholar
  95. Rangaswami H, Bulbule A, Kundu GC (2006) Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16:79–87.  https://doi.org/10.1016/j.tcb.2005.12.005CrossRefPubMedGoogle Scholar
  96. Riabov V, Gudima A, Wang N, Mickley A, Orekhov A, Kzhyshkowska J (2014) Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol 5:75.  https://doi.org/10.3389/fphys.2014.00075CrossRefPubMedPubMedCentralGoogle Scholar
  97. Romano M, DE Francesco F, Zarantonello L, Ruffolo C, Ferraro GA, Zanus G, Giordano A, Bassi N, Cillo U (2016) From inflammation to Cancer in inflammatory bowel disease: molecular perspectives. Anticancer Res 36:1447–1460PubMedGoogle Scholar
  98. Roque AT, Gambeloni RZ, Felitti S, Ribeiro ML, Santos JC (2015) Inflammation-induced oxidative stress in breast cancer patients. Med Oncol Northwood Lond Engl 32:263.  https://doi.org/10.1007/s12032-015-0709-5CrossRefGoogle Scholar
  99. Ryder M, Ghossein RA, Ricarte-Filho JCM, Knauf JA, Fagin JA (2008) Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer 15:1069–1074.  https://doi.org/10.1677/ERC-08-0036CrossRefPubMedPubMedCentralGoogle Scholar
  100. Sanford JR (2004) Pre-mRNA splicing: life at the centre of the central dogma. J Cell Sci 117:6261–6263.  https://doi.org/10.1242/jcs.01513CrossRefPubMedGoogle Scholar
  101. Schoppmann SF, Birner P, Stöckl J, Kalt R, Ullrich R, Caucig C, Kriehuber E, Nagy K, Alitalo K, Kerjaschki D (2002) Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 161:947–956.  https://doi.org/10.1016/S0002-9440(10)64255-1CrossRefPubMedPubMedCentralGoogle Scholar
  102. Selek A, Cetinarslan B, Tarkun I, Canturk Z, Ustuner B, Akyay Z (2017) Thyroid autoimmunity: is really associated with papillary thyroid carcinoma? Eur Arch Oto-Rhino-Laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc EUFOS Affil Ger Soc Oto-Rhino-Laryngol – Head Neck Surg 274:1677–1681.  https://doi.org/10.1007/s00405-016-4414-6CrossRefGoogle Scholar
  103. Senbanjo LT, Chellaiah MA (2017) CD44: a multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of Cancer cells. Front Cell Dev Biol 5.  https://doi.org/10.3389/fcell.2017.00018
  104. Shilo A, Ben Hur V, Denichenko P, Stein I, Pikarsky E, Rauch J, Kolch W, Zender L, Karni R (2014) Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling a-Raf splicing in hepatocellular carcinoma development. RNA 20:505–515.  https://doi.org/10.1261/rna.042259.113CrossRefPubMedPubMedCentralGoogle Scholar
  105. Shultz JC, Goehe RW, Wijesinghe DS, Murudkar C, Hawkins AJ, Shay JW, Minna JD, Chalfant CE (2010) Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a. Cancer Res 70:9185–9196.  https://doi.org/10.1158/0008-5472.CAN-10-1545CrossRefPubMedPubMedCentralGoogle Scholar
  106. Silva AL, Carmo F, Bugalho MJ (2013) RAC1b overexpression in papillary thyroid carcinoma: a role to unravel. Eur J Endocrinol Eur Fed Endocr Soc 168:795–804.  https://doi.org/10.1530/EJE-12-0960CrossRefGoogle Scholar
  107. Song E, Jeon MJ, Park S, Kim M, Oh H-S, Song DE, Kim WG, Kim WB, Shong YK, Kim TY (2018a) Influence of coexistent Hashimoto’s thyroiditis on the extent of cervical lymph node dissection and prognosis in papillary thyroid carcinoma. Clin Endocrinol 88:123–128.  https://doi.org/10.1111/cen.13475CrossRefGoogle Scholar
  108. Song X, Zeng Z, Wei H, Wang Z (2018b) Alternative splicing in cancers: from aberrant regulation to new therapeutics. Semin Cell Dev Biol 75:13–22.  https://doi.org/10.1016/j.semcdb.2017.09.018CrossRefPubMedGoogle Scholar
  109. Stallings-Mann ML, Waldmann J, Zhang Y, Miller E, Gauthier ML, Visscher DW, Downey GP, Radisky ES, Fields AP, Radisky DC (2012) Matrix metalloproteinase induction of Rac1b, a key effector of lung cancer progression. Sci Transl med 4:142ra95.  https://doi.org/10.1126/scitranslmed.3004062CrossRefGoogle Scholar
  110. Sun D, Novotny M, Bulek K, Liu C, Li X, Hamilton T (2011) Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF). Nat Immunol 12:853–860.  https://doi.org/10.1038/ni.2081CrossRefPubMedPubMedCentralGoogle Scholar
  111. Takahashi H, Nishimura J, Kagawa Y, Kano Y, Takahashi Y, Wu X, Hiraki M, Hamabe A, Konno M, Haraguchi N, Takemasa I, Mizushima T, Ishii M, Mimori K, Ishii H, Doki Y, Mori M, Yamamoto H (2015) Significance of polypyrimidine tract-binding protein 1 expression in colorectal cancer. Mol Cancer Ther 14:1705–1716.  https://doi.org/10.1158/1535-7163.MCT-14-0142CrossRefPubMedGoogle Scholar
  112. Taniguchi K, Sugito N, Kumazaki M, Shinohara H, Yamada N, Matsuhashi N, Futamura M, Ito Y, Otsuki Y, Yoshida K, Uchiyama K, Akao Y (2015) Positive feedback of DDX6/c-Myc/PTB1 regulated by miR-124 contributes to maintenance of the Warburg effect in colon cancer cells. Biochim Biophys Acta 1852:1971–1980.  https://doi.org/10.1016/j.bbadis.2015.06.022CrossRefPubMedGoogle Scholar
  113. Tauler J, Mulshine JL (2009) Lung cancer and inflammation: interaction of chemokines and hnRNPs. Curr Opin Pharmacol 9:384–388.  https://doi.org/10.1016/j.coph.2009.06.004CrossRefPubMedGoogle Scholar
  114. Tessner TG, Muhale F, Riehl TE, Anant S, Stenson WF (2004) Prostaglandin E2 reduces radiation-induced epithelial apoptosis through a mechanism involving AKT activation and bax translocation. J Clin Invest 114:1676–1685.  https://doi.org/10.1172/JCI22218CrossRefPubMedPubMedCentralGoogle Scholar
  115. Tilli TM, Franco VF, Robbs BK, Wanderley JLM, de Azevedo da Silva FR, de Mello KD, Viola JPB, Weber GF, Gimba ER (2011) Osteopontin-c splicing isoform contributes to ovarian Cancer progression. Mol Cancer Res 9:280–293.  https://doi.org/10.1158/1541-7786.MCR-10-0463CrossRefPubMedGoogle Scholar
  116. Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, Apuzzo T, Sperduti I, Volpe S, Cocorullo G, Gulotta G, Dieli F, De Maria R, Stassi G (2014) CD44v6 is a marker of constitutive and reprogrammed Cancer stem cells driving colon cancer metastasis. Cell Stem Cell 14:342–356.  https://doi.org/10.1016/j.stem.2014.01.009CrossRefPubMedGoogle Scholar
  117. Urbanski LM, Leclair N, Anczuków O (2018) Alternative-splicing defects in cancer: splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics. Wiley Interdiscip Rev RNA 9:e1476.  https://doi.org/10.1002/wrna.1476CrossRefPubMedPubMedCentralGoogle Scholar
  118. Venables JP, Klinck R, Koh C, Gervais-Bird J, Bramard A, Inkel L, Durand M, Couture S, Froehlich U, Lapointe E, Lucier J-F, Thibault P, Rancourt C, Tremblay K, Prinos P, Chabot B, Elela SA (2009) Cancer-associated regulation of alternative splicing. Nat Struct Amp Mol Biol 16:670CrossRefGoogle Scholar
  119. Villalba M, Evans SR, Vidal-Vanaclocha F, Calvo A (2017) Role of TGF-β in metastatic colon cancer: it is finally time for targeted therapy. Cell Tissue Res 370:29–39.  https://doi.org/10.1007/s00441-017-2633-9CrossRefPubMedGoogle Scholar
  120. Wai PY, Kuo PC (2008) Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 27:103–118.  https://doi.org/10.1007/s10555-007-9104-9CrossRefPubMedGoogle Scholar
  121. Wakefield LM, Hill CS (2013) Beyond TGFβ: roles of other TGFβ superfamily members in cancer. Nat Rev Cancer 13:328–341.  https://doi.org/10.1038/nrc3500CrossRefPubMedGoogle Scholar
  122. Weber GF (2001) The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta BBA – Rev Cancer 1552:61–85.  https://doi.org/10.1016/S0304-419X(01)00037-3CrossRefGoogle Scholar
  123. Xu Z, Weiss A (2002) Negative regulation of CD45 by differential homodimerization of the alternatively spliced isoforms. Nat Immunol 3:764–771.  https://doi.org/10.1038/ni822CrossRefPubMedGoogle Scholar
  124. Xu X, Wei Y, Wang S, Luo M, Zeng H (2017) Serine-arginine protein kinase 1 (SRPK1) is elevated in gastric cancer and plays oncogenic functions. Oncotarget 8:61944–61957.  https://doi.org/10.18632/oncotarget.18734CrossRefPubMedPubMedCentralGoogle Scholar
  125. Xue Y, Zhou Y, Wu T, Zhu T, Ji X, Kwon Y-S, Zhang C, Yeo G, Black DL, Sun H, Fu X-D, Zhang Y (2009) Genome-wide analysis of PTB-RNA interactions reveals a strategy used by the general splicing repressor to modulate exon inclusion or skipping. Mol Cell 36:996–1006.  https://doi.org/10.1016/j.molcel.2009.12.003CrossRefPubMedPubMedCentralGoogle Scholar
  126. Zhou C, Licciulli S, Avila JL, Cho M, Troutman S, Jiang P, Kossenkov AV, Showe LC, Liu Q, Vachani A, Albelda SM, Kissil JL (2012a) The Rac1 splice form Rac1b promotes K-Ras-induced lung tumorigenesis. Oncogene.  https://doi.org/10.1038/onc.2012.99CrossRefGoogle Scholar
  127. Zhou Z, Qiu J, Liu W, Zhou Y, Plocinik RM, Li H, Hu Q, Ghosh G, Adams JA, Rosenfeld MG, Fu X-D (2012b) The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus. Mol Cell 47:422–433.  https://doi.org/10.1016/j.molcel.2012.05.014CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Ana Luísa Silva
    • 1
    • 2
  • Márcia Faria
    • 1
    • 3
  • Paulo Matos
    • 3
    • 4
  1. 1.Serviço de Endocrinologia, Diabetes e Metabolismo do CHLN-Hospital Santa MariaLisbonPortugal
  2. 2.ISAMB-Instituto de Saúde Ambiental, Faculdade de Medicina da Universidade de LisboaLisbonPortugal
  3. 3.Faculdade de Ciências, BioISI-Biosystems and Integrative Sciences InstituteUniversidade de LisboaLisbonPortugal
  4. 4.Departamento de Genética HumanaInstituto Nacional de Saúde Doutor Ricardo JorgeLisbonPortugal

Personalised recommendations